

15. (new) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of from about 100 mg. to about 300 mg., per tablet.

16. (new) The therapeutic compositions of claim 15, wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

17. (new) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

18. (new) The therapeutic compositions of claim 17, wherein said suspensions

contain about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

19. (new) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of about 100 mg. to about 300 mg. guaifenesin, per tablet.

20. (new) The method of claim 19 wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

21. (new) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to

about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

*R*  
*com.*  
22. (new) The method of claim 21 wherein said suspension form contains about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

---